Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo F Mora

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Journal of Family Practice|October 10, 2017
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Basal insulinsPablo F Mora
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|June 3, 2010
New-onset diabetes after renal transplantationPablo F Mora
The American Journal of the Medical Sciences|February 16, 2005
Post-transplantation diabetes mellitusPablo F Mora
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 8, 2016
CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?Pablo F Mora, Eric L Johnson
Endocrine Research|December 20, 2007
Insulin therapy in type 2 diabetesKathleen L Wyne, Pablo F Mora
Journal of the American Academy of Nurse Practitioners|September 24, 2002
Use of an insulin pen by homeless patients with diabetes mellitusTerry Wilk, Pablo F Mora, Susan Chaney, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|December 11, 2012
Type 1 diabetes treatment beyond insulin: role of GLP-1 analogsLindsay B Harrison, Pablo F Mora, Gregory O Clark, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 27, 2019
EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETESPablo F Mora, Jason Chao, Aramesh Saremi, et al.
BMJ Open Diabetes Research & Care|November 20, 2020
Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetesPablo F Mora, David R Sutton, Ashwini Gore, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Journal of Family Practice|October 10, 2017
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Basal insulinsPablo F Mora
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|June 3, 2010
New-onset diabetes after renal transplantationPablo F Mora
The American Journal of the Medical Sciences|February 16, 2005
Post-transplantation diabetes mellitusPablo F Mora
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 8, 2016
CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?Pablo F Mora, Eric L Johnson
Endocrine Research|December 20, 2007
Insulin therapy in type 2 diabetesKathleen L Wyne, Pablo F Mora
Journal of the American Academy of Nurse Practitioners|September 24, 2002
Use of an insulin pen by homeless patients with diabetes mellitusTerry Wilk, Pablo F Mora, Susan Chaney, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|December 11, 2012
Type 1 diabetes treatment beyond insulin: role of GLP-1 analogsLindsay B Harrison, Pablo F Mora, Gregory O Clark, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 27, 2019
EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETESPablo F Mora, Jason Chao, Aramesh Saremi, et al.
BMJ Open Diabetes Research & Care|November 20, 2020
Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetesPablo F Mora, David R Sutton, Ashwini Gore, et al.
Pageof 1